Who Supplies Losartan to India from JAPAN

Importing finished pharmaceutical formulations containing Losartan into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before registration and import. Applications for registration and import must be submitted to the Drugs Controller General (India) at CDSCO.

Imported pharmaceutical formulations must undergo testing at CDSCO-approved laboratories. Batch-wise testing is required, with Certificates of Analysis (CoA) provided for each batch. Stability data must comply with International Council for Harmonisation (ICH) guidelines for Zone IV. Products must meet the standards of the Indian Pharmacopoeia. Port inspections by customs drug inspectors are conducted to ensure compliance.

In April 2025, the CDSCO introduced mandatory import registration and licensing for all imported medicines to prevent the sale of unapproved or illegal drugs in India. This regulation requires importers to obtain registration and licenses from CDSCO as per the Drugs and Cosmetics Act and Rules.

India imports finished Losartan formulations to meet the demand for branded and patented products, specialized dosage forms, and formulations not produced domestically. The Indian market for Losartan formulations is substantial, with a total export value of $301 million across 506 exporters to 141 countries.

The import duty for finished pharmaceutical formulations containing Losartan (HS Code 30049073) includes a Basic Customs Duty of 10%, a Social Welfare Surcharge of 10%, and an Integrated Goods and Services Tax (IGST) of 12%. Additional duties may apply based on specific circumstances.

India sources finished Losartan formulations from Japan due to Japan's competitive advantages, including patented formulations, specialized dosage forms, and high-quality manufacturing standards. Other suppliers include China, Germany, and the United States, but Japan's share in the Indian market is significant.

India imports Losartan formulations from Japan due to Japan's production of patented formulations, specialized dosage forms, and high-quality manufacturing processes. These products meet specific therapeutic needs and quality standards not always available from domestic sources.

Compared to other origins like China, the European Union, and the United States, Japan offers advantages in terms of product quality, regulatory compliance, and reliability. Japan's unique advantage lies in its advanced pharmaceutical manufacturing technologies and adherence to international quality standards.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. There have been no significant shortages reported in recent years.

1. 1Engage in dual-sourcing strategies to mitigate supply chain risks.
2. 2Implement robust inventory planning to manage demand fluctuations.
3. 3Establish favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Negotiate Minimum Order Quantities (MOQs) that align with market demand.
5. 5Conduct thorough supplier qualification processes to ensure compliance with quality and regulatory standards.

1. 1Obtain a valid Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Register the product with CDSCO using Form 40/41.
3. 3Secure a Drug Import License from CDSCO.
4. 4Obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare, if required.
5. 5Engage a licensed customs broker for import clearance.
6. 6Seek an advance ruling for HS Code 30049073 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF) for the product.
5. 5Stability data compliant with ICH Zone IVa/IVb guidelines.
6. 6Free Sale Certificate indicating the product is freely sold in the country of origin.
7. 7Manufacturer's authorization letter.

Upon arrival, customs drug inspectors collect samples for mandatory batch testing. The testing process includes verification of CoA, stability data, and compliance with Indian Pharmacopoeia standards. If a batch fails, it may be rejected, re-exported, or destroyed, depending on the severity of the non-compliance. Common quality issues from Japan include labeling discrepancies and packaging defects.

1. 1Renew CDSCO registration annually.
2. 2Undergo periodic audits in Japan to ensure continued compliance with manufacturing standards.
3. 3Implement change control procedures for any modifications in manufacturing processes or formulations.
4. 4Establish a pharmacovigilance system for post-market monitoring of adverse events.
5. 5Maintain import records as per the Drugs and Cosmetics Act for regulatory inspections.